Cargando…
Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients
Background: Fosaprepitant-associated injection site reaction (ISR) has been reported in patients treated with cisplatin, an irritant drug. We conducted this retrospective study to clarify the incidence and symptoms of fosaprepitant-associated ISR in patients treated with anthracycline. Patients and...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007527/ https://www.ncbi.nlm.nih.gov/pubmed/24799957 http://dx.doi.org/10.7150/jca.7706 |
_version_ | 1782314342189891584 |
---|---|
author | Sato, Yumiko Kondo, Masahiro Inagaki, Atsushi Komatsu, Hirokazu Okada, Chika Naruse, Kumi Sahashi, Tomoyo Kuroda, Junko Ogura, Hiroka Uegaki, Shiori Yoshida, Tatsuya Mori, Yoshinori Sawada, Hiroo Watanabe, Shoichi Sugiura, Hiroshi Endo, Yumi Yoshimoto, Nobuyasu Toyama, Tatsuya Iida, Shinsuke Yamada, Koichi Kimura, Kazunori Wakita, Atsushi |
author_facet | Sato, Yumiko Kondo, Masahiro Inagaki, Atsushi Komatsu, Hirokazu Okada, Chika Naruse, Kumi Sahashi, Tomoyo Kuroda, Junko Ogura, Hiroka Uegaki, Shiori Yoshida, Tatsuya Mori, Yoshinori Sawada, Hiroo Watanabe, Shoichi Sugiura, Hiroshi Endo, Yumi Yoshimoto, Nobuyasu Toyama, Tatsuya Iida, Shinsuke Yamada, Koichi Kimura, Kazunori Wakita, Atsushi |
author_sort | Sato, Yumiko |
collection | PubMed |
description | Background: Fosaprepitant-associated injection site reaction (ISR) has been reported in patients treated with cisplatin, an irritant drug. We conducted this retrospective study to clarify the incidence and symptoms of fosaprepitant-associated ISR in patients treated with anthracycline. Patients and methods: Fifty six patients receiving 159 injections administering doxorubicin/cyclophosphamide (AC), fluorouracil/epirubicin/cyclophosphamide (FEC), or rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone (R-)CHOP regimen through a peripheral vein at ambulatory treatment centers reviewed for this study from patients' medical records. Incidence of ISR was compared between 24 patients with fosaprepitant injection (fosaprepitant group) and 32 patients without fosaprepitant (control group). Frequency and symptoms of ISR per injection were also compared between 61 injections with fosaprepitant and 98 injections without fosaprepitant. Results: Both the ISR incidence rate per patient and per injection were significantly higher in the fosaprepitant group than in the control group (67% vs. 16%; P=0.0002, 34% vs. 8.2%; P<0.0001, respectively). By multivariate analysis, fosaprepitant injection was found to be a significant independent variable correlated with ISR risk. Symptoms observed in 61 injections of fosaprepitant were pain (n=14, 23%), erythema (n=10, 16%), swelling (n=6, 10%), and delayed drip infusion (n=6, 10%). After the observation period, no ISR occurred when the administration route was changed to central venous injection or oral aprepitant was administered despite the continuation of chemotherapy. Conclusion: ISR occurred more frequently and severely when fosaprepitant was injected through the peripheral vein in patients treated with anthracyclines compared to those without fosaprepitant. |
format | Online Article Text |
id | pubmed-4007527 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-40075272014-05-05 Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients Sato, Yumiko Kondo, Masahiro Inagaki, Atsushi Komatsu, Hirokazu Okada, Chika Naruse, Kumi Sahashi, Tomoyo Kuroda, Junko Ogura, Hiroka Uegaki, Shiori Yoshida, Tatsuya Mori, Yoshinori Sawada, Hiroo Watanabe, Shoichi Sugiura, Hiroshi Endo, Yumi Yoshimoto, Nobuyasu Toyama, Tatsuya Iida, Shinsuke Yamada, Koichi Kimura, Kazunori Wakita, Atsushi J Cancer Research Paper Background: Fosaprepitant-associated injection site reaction (ISR) has been reported in patients treated with cisplatin, an irritant drug. We conducted this retrospective study to clarify the incidence and symptoms of fosaprepitant-associated ISR in patients treated with anthracycline. Patients and methods: Fifty six patients receiving 159 injections administering doxorubicin/cyclophosphamide (AC), fluorouracil/epirubicin/cyclophosphamide (FEC), or rituximab/cyclophosphamide/doxorubicin/vincristine/prednisolone (R-)CHOP regimen through a peripheral vein at ambulatory treatment centers reviewed for this study from patients' medical records. Incidence of ISR was compared between 24 patients with fosaprepitant injection (fosaprepitant group) and 32 patients without fosaprepitant (control group). Frequency and symptoms of ISR per injection were also compared between 61 injections with fosaprepitant and 98 injections without fosaprepitant. Results: Both the ISR incidence rate per patient and per injection were significantly higher in the fosaprepitant group than in the control group (67% vs. 16%; P=0.0002, 34% vs. 8.2%; P<0.0001, respectively). By multivariate analysis, fosaprepitant injection was found to be a significant independent variable correlated with ISR risk. Symptoms observed in 61 injections of fosaprepitant were pain (n=14, 23%), erythema (n=10, 16%), swelling (n=6, 10%), and delayed drip infusion (n=6, 10%). After the observation period, no ISR occurred when the administration route was changed to central venous injection or oral aprepitant was administered despite the continuation of chemotherapy. Conclusion: ISR occurred more frequently and severely when fosaprepitant was injected through the peripheral vein in patients treated with anthracyclines compared to those without fosaprepitant. Ivyspring International Publisher 2014-04-24 /pmc/articles/PMC4007527/ /pubmed/24799957 http://dx.doi.org/10.7150/jca.7706 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Research Paper Sato, Yumiko Kondo, Masahiro Inagaki, Atsushi Komatsu, Hirokazu Okada, Chika Naruse, Kumi Sahashi, Tomoyo Kuroda, Junko Ogura, Hiroka Uegaki, Shiori Yoshida, Tatsuya Mori, Yoshinori Sawada, Hiroo Watanabe, Shoichi Sugiura, Hiroshi Endo, Yumi Yoshimoto, Nobuyasu Toyama, Tatsuya Iida, Shinsuke Yamada, Koichi Kimura, Kazunori Wakita, Atsushi Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients |
title | Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients |
title_full | Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients |
title_fullStr | Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients |
title_full_unstemmed | Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients |
title_short | Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients |
title_sort | highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007527/ https://www.ncbi.nlm.nih.gov/pubmed/24799957 http://dx.doi.org/10.7150/jca.7706 |
work_keys_str_mv | AT satoyumiko highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT kondomasahiro highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT inagakiatsushi highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT komatsuhirokazu highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT okadachika highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT narusekumi highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT sahashitomoyo highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT kurodajunko highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT ogurahiroka highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT uegakishiori highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT yoshidatatsuya highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT moriyoshinori highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT sawadahiroo highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT watanabeshoichi highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT sugiurahiroshi highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT endoyumi highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT yoshimotonobuyasu highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT toyamatatsuya highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT iidashinsuke highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT yamadakoichi highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT kimurakazunori highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients AT wakitaatsushi highlyfrequentandenhancedinjectionsitereactioninducedbyperipheralvenousinjectionoffosaprepitantinanthracyclinetreatedpatients |